November 2020 in “Elsevier eBooks” This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
8 citations
,
November 2015 in “Saudi Journal of Biological Sciences” This study found that KH053, combining Panax ginseng and bee-pollen, significantly reduced prostate weight and DHT levels, inhibiting BPH development in a rat model.
May 2026 in “International Journal of Drug Delivery Technology” This source describes how androgenic alopecia, or pattern hair loss, affects about 70% of men and is linked to factors like stress, hormonal imbalances, and lifestyle issues, which can also impact psychological well-being and potentially contribute to severe health conditions such as heart disease.
14 citations
,
November 2006 in “Current Medicinal Chemistry” This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.
11 citations
,
December 2018 in “Assay and Drug Development Technologies” This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.